Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Basal-cell carcinoma

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise nodular, superficial, morphoeic and pigmented basal-cell carcinoma, stratify anatomical and histological risk, refer appropriately and explain why apparently slow growth can still cause major local destruction.

  • Nodular BCC is a pearly or translucent papule with arborising vessels, rolled edge and possible central ulceration.
  • Superficial BCC is a thin pink-red, brown or subtly pigmented scaly plaque, often on trunk, and can resemble eczema.
  • Morphoeic BCC appears scar-like, firm, pale or yellow-white and poorly defined; its subclinical extension makes it high risk.
  • Pigmented BCC occurs in every skin tone and can mimic melanoma; refer diagnostic uncertainty without destructive treatment.
  • Most low-risk BCCs are referred routinely, but NICE advises urgent referral when delay could materially affect outcome because of site or size.
  • Surgical excision is standard for many tumours; Mohs surgery is considered where tissue conservation and complete margin control matter.
  • Topical imiquimod, topical 5-fluorouracil, curettage, cryotherapy or photodynamic therapy suit selected low-risk superficial lesions after diagnosis.
  • Metastasis is rare, but local invasion can be severe; new pain, numbness, weakness or fixation is not compatible with casual routine follow-up.

Key red flags

Rapid change, deep fixation, cranial-nerve symptoms, recurrent tumour, ill-defined morphoeic plaque, large neglected ulcer or periocular, nasal, lip or ear disease threatens critical structures and requires urgent specialist assessment.

Morphoeic scar-like plaque

An indurated ivory or yellow-white poorly defined plaque can extend well beyond what is visible.

Perineural warning

New pain, paraesthesia, numbness or weakness near a tumour suggests nerve invasion and requires urgent escalation.

Investigation priorities

01
DermoscopyFirst step

Identify arborising vessels, shiny white structures, ulceration, leaf-like areas and blue-grey nests.

Management branches

Low-risk suspected BCCObtain diagnosis and definitive care

A well-defined primary lesion is away from high-risk sites and lacks aggressive features.

  1. Document site, size, border and dermoscopy and refer through the local routine BCC pathway when clinically appropriate.
  2. Use standard excision with histology for many lesions or a selected non-surgical option for confirmed superficial low-risk disease.
  3. Review pathology, healing and recurrence advice and support ultraviolet protection and whole-skin awareness.

Key medicines

Imiquimod 5% creamFor selected small superficial BCC, apply five times weekly for six weeks according to the licensed product and specialist-confirmed plan.Expected inflammation can be marked; avoid eyes and mucosa, review non-response, pregnancy and immune status, and do not use for nodular or high-risk disease without specialist direction.
Open full textbook →Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists basal-cell carcinomaMorphology, subtypes, treatment and recurrence.
  • NICE NG12 suspected skin cancer referralRoutine versus urgent BCC referral.
  • Aldara 5% cream SmPCLicensed superficial BCC regimen and cautions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom